{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:17Z","timestamp":1785510497856,"version":"3.56.0"},"reference-count":45,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    The recently approved first-in-class combination therapy xanomeline\/trospium chloride (KarXT) demonstrated superiority over placebo in three randomized controlled trials (RCTs) of adults with schizophrenia. This analysis investigates its relative efficacy, safety and tolerability compared with eight second-generation antipsychotics for the acute treatment of schizophrenia via network meta-analyses (NMAs).\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A 2019 systematic literature review was adapted and updated to identify RCTs of eight antipsychotics in adults with schizophrenia. NMAs were conducted to compare KarXT against these antipsychotics for 11 endpoints of interest, measured at 4\u20136\u00a0weeks, covering efficacy (Positive and Negative Syndrome Scale [PANSS]; Clinical Global Impressions \u2013 Severity [CGI-S]), safety (weight change, sedation and somnolence) and tolerability (discontinuation; all-cause and due to adverse events).\n                    <jats:bold>Results:<\/jats:bold>\n                    A network of 49 RCTs including 14,680 patients was formed. KarXT was associated with greater odds of clinical response (\u226530% improvement in PANSS total score) than aripiprazole (odds ratio [OR]: 1.85; 95% credible interval [CrI]: 1.11, 3.11), brexpiprazole (OR: 2.23; 95% CrI: 1.34, 3.83) and cariprazine (OR: 2.05; 95% CrI: 1.19, 3.57); improved change from baseline (CFB) PANSS positive symptoms score versus brexpiprazole; improved CFB CGI-S score against aripiprazole, brexpiprazole, cariprazine and olanzapine; reduced odds of clinically significant (\u22657%) weight gain over all comparators except clozapine (no data); improved CFB weight against brexpiprazole, clozapine, olanzapine, quetiapine and risperidone; and greater odds of all-cause discontinuation than aripiprazole, brexpiprazole, clozapine, lumateperone, olanzapine, quetiapine and risperidone.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In this NMA, for patients receiving acute treatment for schizophrenia, KarXT compared favorably with second-generation antipsychotics on key efficacy endpoints and in terms of unwanted weight gain.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0045","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:46:47Z","timestamp":1785422807000},"source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and network meta-analysis of the efficacy, safety and tolerability of xanomeline plus trospium chloride compared with eight oral antipsychotics for the acute treatment of schizophrenia"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2310-6265","authenticated-orcid":false,"given":"Conor","family":"Hickey","sequence":"first","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F","family":"Sidovar","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08648, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-2608","authenticated-orcid":false,"given":"Andrea","family":"Garcia","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5382-0287","authenticated-orcid":false,"given":"Ken","family":"Kramer","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08648, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-5246","authenticated-orcid":false,"given":"Jen-Yu Amy","family":"Chang","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1082-7081","authenticated-orcid":false,"given":"Katrin","family":"Kupas","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, NE, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshnavi","family":"Telukuntla","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Horgan","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0116-3110","authenticated-orcid":false,"given":"Haris","family":"Jameel","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Westley","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-2878","authenticated-orcid":false,"given":"Kristin K","family":"Gillard","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08648, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Cutler","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University, Lakewood Ranch, FL 34202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_7_3_2","first-page":"300","article-title":"Schizophrenia: an overview","volume":"14","author":"Rahman T","year":"2016","unstructured":"Rahman T, Lauriello J. Schizophrenia: an overview. Focus (Am. Psychiatr. Publ.) 14(3), 300\u2013307 (2016).","journal-title":"Focus (Am. Psychiatr. Publ.)"},{"issue":"8","key":"e_1_3_7_4_2","first-page":"870","article-title":"Unmet needs in schizophrenia","volume":"16","author":"Pompili M","year":"2017","unstructured":"Pompili M, Giordano G, Luciano M Unmet needs in schizophrenia. CNS Neurol. Disord. Drug Targets 16(8), 870\u2013884 (2017).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"5","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon RA","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol. Psychiatry 28(5), 1902\u20131918 (2023).","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi M","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol. Psychiatry 28(12), 5319\u20135327 (2023).","journal-title":"Mol. Psychiatry"},{"issue":"10100","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100), 1211\u20131259 (2017).","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9(2), 137\u2013150 (2022).","journal-title":"Lancet Psychiatry"},{"key":"e_1_3_7_9_2","article-title":"Mental and Substance use disorders prevalence study (MDPS): findings report","author":"Ringeisen H","year":"2023","unstructured":"Ringeisen H, Edlund MJ, Guyer H Mental and Substance use disorders prevalence study (MDPS): findings report. RTI International (2023). (19 December 2024). Available at: https:\/\/www.rti.org\/publication\/mental-substance-use-disorders-prevalence-study-findings-report","journal-title":"RTI International"},{"issue":"12","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson M","year":"2015","unstructured":"Olfson M, Gerhard T, Huang C Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 72(12), 1172\u20131181 (2015).","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia","volume":"177","author":"Keepers GA","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am. J. Psychiatry 177(9), 868\u2013872 (2020).","journal-title":"Am. J. Psychiatry"},{"issue":"29","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li P","year":"2016","unstructured":"Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr. Top Med. Chem. 16(29), 3385\u20133403 (2016).","journal-title":"Curr. Top Med. Chem."},{"issue":"1","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02245602","article-title":"Mechanisms of action of atypical antipsychotic drugs: a critical analysis","volume":"124","author":"Kinon BJ","year":"1996","unstructured":"Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.) 124(1\u20132), 2\u201334 (1996).","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"DiBonaventura M","year":"2012","unstructured":"DiBonaventura M, Gabriel S, Dupclay L A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 12(1), 20 (2012).","journal-title":"BMC Psychiatry"},{"issue":"1","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41537-024-00448-2","article-title":"Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system","volume":"10","author":"Rivelli A","year":"2024","unstructured":"Rivelli A, Fitzpatrick V, Nelson M Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system. Schizophrenia 10(1), 28 (2024).","journal-title":"Schizophrenia"},{"key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/NDT.S501560","article-title":"A clinically oriented review of new antipsychotics for schizophrenia","volume":"20","author":"Luca M","year":"2024","unstructured":"Luca M, Luca A, Serretti A. A clinically oriented review of new antipsychotics for schizophrenia. Neuropsychiatr. Dis. Treat. 20, 2637\u20132649 (2024).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"e_1_3_7_17_2","article-title":"AbbVie provides update on phase 2 results for emraclidine in schizophrenia","author":"AbbVie","year":"2024","unstructured":"AbbVie. AbbVie provides update on phase 2 results for emraclidine in schizophrenia. [08 January 2025] (2024). https:\/\/news.abbvie.com\/2024-11-11-AbbVie-Provides-Update-on-Phase-2-Results-for-Emraclidine-in-Schizophrenia","journal-title":"08 January 2025"},{"issue":"13","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1021\/acs.jmedchem.4c00293","article-title":"Design and synthesis of clinical candidate PF-06852231 (CVL-231): a brain penetrant, selective, positive allosteric modulator of the M4 muscarinic acetylcholine receptor","volume":"67","author":"Butler CR","year":"2024","unstructured":"Butler CR, Popiolek M, McAllister LA Design and synthesis of clinical candidate PF-06852231 (CVL-231): a brain penetrant, selective, positive allosteric modulator of the M4 muscarinic acetylcholine receptor. J. Med. Chem. 67(13), 10831\u201310847 (2024).","journal-title":"J. Med. Chem."},{"issue":"1","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action","volume":"371","author":"Dedic N","year":"2019","unstructured":"Dedic N, Jones PG, Hopkins SC SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J. Pharmacol. Exp. Ther. 371(1), 1\u201314 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_7_20_2","unstructured":"Sumitomo Pharma. Sumitomo Pharma and Otsuka announce topline results from phase 3 DIAMOND 1 and DIAMOND 2 clinical studies evaluating ulotaront in schizophrenia (2023). https:\/\/www.sumitomo-pharma.com\/news\/20230731-1.html"},{"key":"e_1_3_7_21_2","article-title":"FDA Approves drug with new mechanism of action for treatment of schizophrenia (2024) [08 January 2025]","author":"US Food and Drug Administration","year":"2024","unstructured":"US Food and Drug Administration. FDA Approves drug with new mechanism of action for treatment of schizophrenia (2024) [08 January 2025]. [08 January 2025] (2024). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia","journal-title":"08 January 2025"},{"issue":"8","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan SK","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N. Engl. J. Med. 384(8), 717\u2013726 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10422","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 403(10422), 160\u2013170 (2024).","journal-title":"Lancet"},{"issue":"8","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul I","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry 81(8), 749\u2013756 (2024).","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40261-024-01377-9","article-title":"Current findings and potential mechanisms of KarXT (xanomeline-trospium) in schizophrenia treatment","volume":"44","author":"Azargoonjahromi A","year":"2024","unstructured":"Azargoonjahromi A. Current findings and potential mechanisms of KarXT (xanomeline-trospium) in schizophrenia treatment. Clin. Drug Investig. 44(7), 471\u2013493 (2024).","journal-title":"Clin. Drug Investig."},{"key":"e_1_3_7_26_2","first-page":"405113201","article-title":"Targeting muscarinic receptors to treat schizophrenia","author":"Foster DJ","year":"2021","unstructured":"Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav. Brain Res. 405113201 (2021).","journal-title":"Behav. Brain Res."},{"issue":"394","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"14","author":"Huhn M","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 14(394), 939\u2013951 (2019).","journal-title":"Lancet"},{"issue":"6","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jval.2024.03.222","article-title":"CO135 comparative efficacy, safety, and tolerability of KarXT versus aripiprazole and cariprazine for the acute treatment of adults with schizophrenia: a network meta-analysis","volume":"27","author":"Hickey C","year":"2024","unstructured":"Hickey C, Cajigal A, Haycroft B CO135 comparative efficacy, safety, and tolerability of KarXT versus aripiprazole and cariprazine for the acute treatment of adults with schizophrenia: a network meta-analysis. Value Health 27(6), S42 (2024).","journal-title":"Value Health"},{"key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","article-title":"A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia","volume":"274","author":"Wright AC","year":"2024","unstructured":"Wright AC, McKenna A, Tice JA A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia. Schizophr. Res. 274, 212\u2013219 (2024).","journal-title":"Schizophr. Res."},{"issue":"1","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"sgaf024","DOI":"10.1093\/schizbullopen\/sgaf024","article-title":"Efficacy and safety of cariprazine, asenapine, xanomeline-trospium, and lumateperone for acute exacerbations of schizophrenia in adults: a network meta-analysis","volume":"6","author":"Abusalameh AA","year":"2025","unstructured":"Abusalameh AA, Ladadweh CR, Hodrob M Efficacy and safety of cariprazine, asenapine, xanomeline-trospium, and lumateperone for acute exacerbations of schizophrenia in adults: a network meta-analysis. Schizophr. Bull. Open 6(1), sgaf024 (2025).","journal-title":"Schizophr. Bull. Open"},{"key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366, 4898 (2019). https:\/\/www.bmj.com\/content\/366\/bmj.l4898.long","journal-title":"BMJ"},{"issue":"10","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani A","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D Graphical tools for network meta-analysis in STATA. PLoS ONE 8(10), e76654 (2013).","journal-title":"PLoS ONE"},{"key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope S","year":"2014","unstructured":"Cope S, Zhang J, Saletan S A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 12, 93 (2014).","journal-title":"BMC Med."},{"key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"152240","DOI":"10.1016\/j.comppsych.2021.152240","article-title":"Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: a six-month naturalistic follow-up study","volume":"108","author":"Vega D","year":"2021","unstructured":"Vega D, Acosta FJ, Saavedra P. Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: a six-month naturalistic follow-up study. Compr. Psychiatry 108, 152240 (2021).","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"e_1_3_7_35_2","first-page":"1","article-title":"Performing meta-analysis with incomplete statistical information in clinical trials","volume":"8","author":"Ma J","year":"2008","unstructured":"Ma J, Liu W, Hunter A Performing meta-analysis with incomplete statistical information in clinical trials. BMC Med. Res. Methodol. 8(1), 1 (2008).","journal-title":"BMC Med. Res. Methodol."},{"key":"e_1_3_7_36_2","article-title":"NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias S","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. [17 December 2024] (2011). https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds","journal-title":"17 December 2024"},{"key":"e_1_3_7_37_2","unstructured":"van Valkenhoef G Kuiper J. gemtc: network meta-analysis using Bayesian methods. Version 1.0-2. (2023). https:\/\/cran.r-project.org\/package=gemtc"},{"issue":"11","key":"e_1_3_7_38_2","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins JP","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"issue":"1","key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef G","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res. Synth. Methods 7(1), 80\u201393 (2016).","journal-title":"Res. Synth. Methods"},{"issue":"4","key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"e002262","DOI":"10.1136\/bmjsem-2024-002262","article-title":"How to conduct and report checking transitivity and inconsistency in network-meta-analysis: a narrative review including practical worked examples, code and source data for sports and exercise medicine researchers","volume":"10","author":"Belav\u00fd DL","year":"2024","unstructured":"Belav\u00fd DL, Kaczorowski S, Saueressig T How to conduct and report checking transitivity and inconsistency in network-meta-analysis: a narrative review including practical worked examples, code and source data for sports and exercise medicine researchers. BMJ Open Sport Exerc. Med. 10(4), e002262 (2024).","journal-title":"BMJ Open Sport Exerc. Med."},{"issue":"11","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/acps.13758","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis","volume":"151","author":"De R","year":"2025","unstructured":"De R, Smith ECC, Navagnanavel J The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica 151(2), 109\u2013126 (2025).","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"e_1_3_7_43_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger T","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 7(1), 64\u201377 (2020).","journal-title":"Lancet Psychiatry"},{"key":"e_1_3_7_44_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan DI","year":"2017","unstructured":"Velligan DI, Sajatovic M, Hatch A Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer. Adherence 11, 449\u2013468 (2017).","journal-title":"Patient Prefer. Adherence"},{"issue":"2","key":"e_1_3_7_45_2","article-title":"Association of antipsychotic-related weight gain with treatment adherence and switching using electronic medical records data","volume":"25","author":"Perkins AJ","year":"2023","unstructured":"Perkins AJ, Khandker R, Overley A Association of antipsychotic-related weight gain with treatment adherence and switching using electronic medical records data. Prim. Care Companion CNS Disord. 25(2), (2023).","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"4","key":"e_1_3_7_46_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1037\/hea0000242","article-title":"Understanding associations among race, socioeconomic status, and health: patterns and prospects","volume":"35","author":"Williams D","year":"2016","unstructured":"Williams D, Priest N, Anderson N. Understanding associations among race, socioeconomic status, and health: patterns and prospects. Health Psychol. 35(4), 407 (2016).","journal-title":"Health Psychol."},{"issue":"4","key":"e_1_3_7_47_2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bpsgos.2023.02.008","article-title":"The placebo effect in psychosis: why it matters and how to measure it","volume":"3","author":"Hird EJ","year":"2023","unstructured":"Hird EJ, Diederen K, Leucht S The placebo effect in psychosis: why it matters and how to measure it. Biol. Psychiatry Glob. Open Sci. 3(4), 605\u2013613 (2023).","journal-title":"Biol. Psychiatry Glob. Open Sci."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:24:25Z","timestamp":1785507865000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.57264\/cer-2026-0045"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0045","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"e260045"}}